Next Article in Journal
A Kitchen with too Many Cooks: Factors Associated with Hospital Profitability
Next Article in Special Issue
Sustainability Orientation and Entrepreneurship Orientation: Is There a Tradeoff Relationship between Them?
Previous Article in Journal
Uncertainty Analysis of the Estimated Risk in Formal Safety Assessment
Previous Article in Special Issue
Participatory Public Service Design by Gov.3.0 Design Group
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessArticle
Sustainability 2018, 10(2), 322; https://doi.org/10.3390/su10020322

Long-Term Collaboration Network Based on ClinicalTrials.gov Database in the Pharmaceutical Industry

Future Information Research Center, Korea Institute of Science and Technology Information, 66 Hoegi-go, Dongdaemun-gu, Seoul 02456, Korea
*
Author to whom correspondence should be addressed.
Received: 12 December 2017 / Revised: 22 January 2018 / Accepted: 23 January 2018 / Published: 26 January 2018
View Full-Text   |   Download PDF [1687 KB, uploaded 26 January 2018]   |  

Abstract

Increasing costs, risks, and productivity problems in the pharmaceutical industry are important recent issues in the biomedical field. Open innovation is proposed as a solution to these issues. However, little statistical analysis related to collaboration in the pharmaceutical industry has been conducted so far. Meanwhile, not many cases have analyzed the clinical trials database, even though it is the information source with the widest coverage for the pharmaceutical industry. The purpose of this study is to test the clinical trials information as a probe for observing the status of the collaboration network and open innovation in the pharmaceutical industry. This study applied the social network analysis method to clinical trials data from 1980 to 2016 in ClinicalTrials.gov. Data were divided into four time periods—1980s, 1990s, 2000s, and 2010s—and the collaboration network was constructed for each time period. The characteristic of each network was investigated. The types of agencies participating in the clinical trials were classified as a university, national institute, company, or other, and the major players in the collaboration networks were identified. This study showed some phenomena related to the pharmaceutical industry that could provide clues to policymakers about open innovation. If follow-up studies were conducted, the utilization of the clinical trial database could be further expanded, which is expected to help open innovation in the pharmaceutical industry. View Full-Text
Keywords: ClinicalTrials.gov; collaboration network; collaborative strategy; pharmaceutical industry; clinical trial study ClinicalTrials.gov; collaboration network; collaborative strategy; pharmaceutical industry; clinical trial study
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Yang, H.; Lee, H.J. Long-Term Collaboration Network Based on ClinicalTrials.gov Database in the Pharmaceutical Industry. Sustainability 2018, 10, 322.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Sustainability EISSN 2071-1050 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top